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n Abstract: The purpose of the study was to review the treatment outcomes of 198 patients treated with breast-conser-
ving surgery (BCS) and whole breast radiation therapy using lung density correction for ductal carcinoma in situ (DCIS).
Between April 1985 and December 2002, 198 patients with 200 lesions diagnosed as DCIS (AJCC stage 0) were treated at
the University of Michigan. All underwent BCS and whole breast radiotherapy. Median total follow-up was 6.2 years (range:
0.8–18.2). The 5- and 10-year cumulative rates of in-breast only failure were 5.9% (95% CI: 2.6–9.3%) and 9.8% (95% CI:
5.2–14.4%), respectively. Factors that significantly predicted for an increased risk of local failure were family history of
breast cancer, positive or close surgical margins and age £ 50 years at diagnosis. Cosmetic outcome was scored as
‘‘excellent’’ or ‘‘good’’ in 94% of the assessed patients. On multivariate analysis, only patient separation significantly predic-
ted cosmetic outcome (p = 0.04). BCS and radiotherapy using lung density correction resulted in high rates of local control
at 5 and 10 years with excellent cosmetic results. To the best of our knowledge, this is the first study to report outcome in
a series of patients with DCIS treated with lung density correction and results compare favorably with other series in which
plans were calculated using unit density. n
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Breast-conserving treatment has become the stand-ard of care for localized ductal carcinoma in situ
(DCIS) of the breast (1). Lumpectomy followed by
whole breast radiation therapy (RT) has been demon-
strated by three large prospective randomized trials to
significantly reduce the risk of local recurrence in the
treated breast by approximately half compared to sur-
gery alone (2–5). This approach allows women to pre-
serve their breasts and avoid the psychological and
physical morbidity associated with mastectomy.
Traditionally, the affected breast has been irradi-
ated with two tangential fields with wedges or
compensatory filters to achieve a homogeneous dose
distribution in the breast without taking into account
the presence of low-density lung tissue in the treat-
ment fields. Treating the whole volume as unit density
results in an underestimation of breast dose by as
much as 10–20% (6,7). Computerized tomography
(CT) enables distinction between different tissue densi-
ties and improves the ability to correctly account for
the low lung density. Use of lung density corrections
can then result in increased dose homogeneity
throughout the treated volume (8,9).
To the best of our knowledge, all published series
of breast-conserving surgery (BCS) and RT for the
treatment of DCIS have included patients with treat-
ment plans calculated without lung density correction.
At the University of Michigan, we have been using
lung density correction as the standard of care for
all patients treated for DCIS since 1985. This
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retrospective report summarizes the results of 198
patients treated with whole breast RT with lung den-
sity correction for dose calculation following BCS for
DCIS. The results demonstrate high rates of local con-
trol using lung density correction.
MATERIALS AND METHODS
Between April 1985 and December 2002, 198
patients with 200 lesions diagnosed as DCIS of the
breast (AJCC stage 0) were treated in the Department
of Radiation Oncology at the University of Michigan.
All patients underwent BCS and whole breast radio-
therapy. Following Institutional Review Board appro-
val, the prospectively maintained Radiation Oncology
data base was queried for the following clinicopatho-
logic characteristics: age, race, weight, menopausal
status, family history of breast cancer (BC) (first- or
second-degree relative with history of BC), means of
diagnosis, surgical procedures, tumor histology and
size, volume excised, margin status, radiation treat-
ment details, systemic hormone therapy, acute and
late toxicity, and cosmetic outcome. In addition to the
slide review at the time of initial diagnosis, all avail-
able pathology slides were re-reviewed at the time of
this analysis for missing nuclear grade information (56
lesions, 28%). Excluded from this analysis are patients
with a prior diagnosis of invasive BC.
Surgery
Surgical therapy consisted of excisional biopsy of
the primary lesion. Resected specimens were routinely
inked to assess microscopic margin status. Sixty-six
percent of the patients underwent re-excision. Final
microscopic margins were defined as positive, close
(defined as £3 mm), or negative (‡3 mm). Axillary
lymph node evaluation was performed in 15% of the
lesions, either by a sentinel lymph node biopsy (4%),
formal axillary lymph node dissection (10%), or both
(1%). All lymph nodes were negative for metastatic
cancer.
Radiotherapy
Whole breast RT was delivered using two opposed
tangential fields. All patients were treated with mega-
voltage radiation, generally 6 MV, to a dose of 46–
50 Gy in 1.8–2.0 Gy fractions over 4.5–5 weeks; a
boost was delivered in 94% of cases. Specifically, the
median dose to the whole breast was 50 Gy (range:
44.1–50.0 Gy); 88% were treated with 6 MV
photons. A boost was delivered using 9 MeV or
12 MeV electrons in 78% of all cases; 12% with
higher electrons energy; 10% received a boost utilizing
photons or a combination of photons and electrons.
The median boost dose was 10 Gy (range: 9.8–
22.0 Gy). The median total tumor bed dose was
60 Gy (range: 48.6–70.6 Gy). No regional lymphatic
radiation was delivered.
All treatment plans were calculated using lung den-
sity correction to correct for the increased photon
transmission through the lung volume in the tangent
fields. Specifically, since the lung mass density is only
0.2 g ⁄ cm3 as opposed to 1 g ⁄ cm3 for soft tissue
(referred to as ‘‘unit density’’) (9), the photon beam
will have decreased attenuation in the lung area. To
compensate for the resultant areas of dose inhomo-
geneity in the breast, a wedge was generally inserted as
compensator in the lateral tangent beam to optimize
the dose distributions at the medial, lateral, and apex
of the breast. Both the dose calculation model and the
treatment-planning system used were three-dimen-
sional. Detailed description of the planning and the
treatment techniques have been described elsewhere
(10,11). Since 2001, all treatment plans have been
generated using CT-based planning.
Follow-up Evaluation
After the completion of RT, patients were followed
at 6-month intervals for 5 years and then yearly.
Office visits included a physical exam and cosmesis
evaluation by the attending physician. The overall cos-
metic result was classified using criteria proposed by
Harris et al. (12), including the presence and severity
of breast edema, retraction, fibrosis, and telangiectasia
(13), where excellent was defined as the treated breast
looks essentially the same as the opposite breast;
good: minimal but identifiable effects of radiation on
the treated breast; fair: significant effect of radiation
on the treated breast; and poor: severe normal tissue
sequelae (12). In addition, for each patient, the fol-
lowing details were documented and incorporated into
the final cosmetic score: presence of fibrosis, size, and
location of telangiectasis and hyper- or hypopigmenta-
tion of the skin (13). Bilateral mammograms were
performed yearly.
Data Analysis
Follow-up information for each patient included the
date of in-breast (local), regional, and ⁄ or distant recur-
rence; contralateral breast cancer (CLBC) diagnosis;
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date of death; or date of last known contact. Time-
to-event end points included loco-regional, local and
distant failure, breast cancer-specific survival and
overall survival. A patient was considered recurrence-
free if free from disease following the completion of
RT until the last known contact date. The time inter-
val to local recurrence was calculated from the com-
pletion of RT until the occurrence of a breast-only
tumor failure or local component of first failure.
Patients experiencing a regional and ⁄ or distant failure
first, or who were disease-free until their last contact
date, were censored at their date of failure or last
contact, respectively. Total follow-up time for each
patient was calculated from the completion of RT
until the last date of contact; total follow-up time
for the entire patient cohort was summarized by
median and range.
The product-limit method of Kaplan–Meier was
used to estimate the overall survival in this population
(14). Confidence intervals were computed using
Greenwood’s estimate of the variance. The cumulative
incidence method was used to estimate the time to
local failure and breast cancer-specific survival, in
order to appropriately account for competing events
(15). Confidence intervals for the cumulative incidence
estimates were based upon point-wise standard error
estimates as calculated by the method of Pepe (16).
For all time-to-event end points, bivariate analyses to
detect significant associations with clinicopathologic
features were conducted using the product-limit
method and log-rank statistics, with censoring occur-
ring at competing events (if present). Multivariate ana-
lyses were conducted using Cox proportional hazards
regression, using only those clinicopathologic features
found to be at least marginally significant (log-rank
p £ .10) during bivariate analysis. Parsimonious mod-
els were constructed using a backward stepwise elim-
ination algorithm, with the models beginning with all
marginally significant features, and a Wald-type
p-value £ .05 necessary for the feature to be retained
in the model. Hazard ratios and 95% confidence inter-
vals are reported.
Cosmetic and acute toxicity end points were ana-
lyzed for association with categorical clinicopathologic
features using the chi-squared or Fisher’s exact test
statistic, and with continuous features using the Krus-
kal–Wallis nonparametric test. Unconditional logistic-
regression was used to create multivariate models for
each endpoint. Parsimonious models were constructed
using only those features found to be at least
marginally significantly associated (p £ .10) with the
endpoint, and the stepwise backward elimination algo-
rithm described above. Models were specifically
designed to predict a cosmesis assessment of ‘‘excel-
lent,’’ and separately the occurrence of acute radi-
ation-induced toxicity grade of at least 2. For all
analyses, missing data for the clinicopathologic
features were assumed to be missing completely
at random.
RESULTS
Patients and Tumor Characteristics
The median total follow-up period was 6.2 years
(range: 0.8–18.2 years). Sixty-two percent (124
patients) had more than 5 years of follow-up; 23%
(46 patients) had more than 10 years of follow-up.
Patient characteristics are summarized in Table 1. The
median age at diagnosis was 53.5 years (range: 30–
83 years).
Tumor characteristics are presented in Table 2.
Eighty-six percent of lesions were diagnosed by
mammogram; re-excision was done in 66% of cases,
and final margins were negative in 89% of cases.
Tamoxifen was prescribed to all patients since the
NSABP B-24 publication in 1999 (17). Forty-seven
patients (24%) were treated with tamoxifen as adju-
vant hormonal therapy, regardless of estrogen receptor
status, according to the study design of the B-24.
Local and Regional Control
The 5- and 10-year cumulative rates of in-breast only
failure were 5.9% (95% CI: 2.6–9.3%) and 9.8%
Table 1. Patient Characteristics
Level N (%)
Age (years) £35 2 (1.0)
36–50 74 (37.0)
>50 124 (62.0)
Race African-American 11 (5.5)
Caucasian 184 (92.0)
Other ⁄ unknown 5 (2.5)





Menopausal status Pre 61 (30.5)
Post 123 (61.5)
Peri 16 (8.0)
Family history of breast cancer 1st degree 29 (14.5)
2nd degree 29 (14.5)
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(95% CI: 5.2–14.4%), respectively (Fig. 1). Break-
down of recurrence by the presence of invasion is pre-
sented in Figure 2. Sixteen patients had a local-only
first failure; 75% (12 ⁄ 16) were DCIS only; and 25%
(4 ⁄ 16) were invasive (3 lobular, 1 ductal). All recur-
rences (100%) were in the same quadrant as the ori-
ginal primary. Fifteen of the 16 patients with in-breast
recurrences were salvaged successfully with mastec-
tomy and one had a repeat lumpectomy. All 16
patients were free of disease at their last follow-up
visit. Four patients not experiencing a local failure
subsequently died as a result of BC: one developed an
ipsilateral axillary recurrence with systemic failure
thereafter; one developed bone metastasis; and two
were diagnosed with locally advanced CLBC and
failed systemically at 15 and 58 months following this
diagnosis.
Factors that significantly predicted for increased
local failure were family history of BC, final margin
status and patient’s age at diagnosis (Table 3). Specif-
ically, the 5-year rate of freedom from local recur-
rence was 83.8% if a patient had a family history of
BC and 97.7% if no family history was present
(p = .029); freedom from local recurrence if the surgi-
cal margins were positive was 62.5% versus 96.6% if
the margins were negative (p = .002). Patients age 50
and younger had 89.4% freedom from local recur-
rence versus 97.0% inpatients older than age 50
(p = .052).
A multivariate Cox proportional hazard regression
revealed that patient’s age at diagnosis (£age 50 versus
>age 50), final surgical margins and family history of
BC were independent predictors for local recurrence
(Table 4).
Survival
As shown in Figure 3, the 5- and 10-year rates of
breast cancer-specific survivals were 100% and 95.9%
Table 2. Tumor Characteristics
Level N (%)

















Final margins status Positive 6 (3.0)
Close (£3 mm) 15 (7.5)
Negative (‡3 mm) 177 (88.5)
Unknown 2 (1.0)
Volume of excision (cm3) Total (n = 156)
Median 70
Range 2–580.0
*DCIS subtypes are not mutually exclusive. A tumor can be characterized as having more
than one subtype.
Figure 1. Cumulative incidence of local first failures.
Figure 2. Cumulative incidence of local first failures by the pres-
ence of invasion at the time of recurrence.
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(95% CI: 91.5–100%), respectively; and the overall
survivals were 98.0% (95% CI: 94.0–99.4%) and
82.4% (95% CI: 72.6–88.9%), respectively.
Contralateral Breast Cancer
Of the 198 patients diagnosed with DCIS, nine
were also diagnosed with either a synchronous or
metachronous CLBC for a crude rate of 4.5%. The
cumulative incidence of CLBC after 5 and 10 years
was 4.3% and 6.0%, respectively. Three cases were
DCIS and six were invasive cancers.
Acute Toxicity Assessment
The maximal acute skin toxicity was reported by a
physician on a weekly basis during RT treatment,
according to the NCI Common Terminology Criteria
for Adverse Events V2 ⁄ 3 (18) and was available for
198 patients (100%). The toxicity was assessed as
grade 0 in 13 patients (6.5%, no toxicity), grade 1 in
93 (46.5%; faint erythema or dry desquamation) and
grade 2 in 94 (47%; moderate to brisk erythema, pat-
chy moist desquamation, mostly confined to skin folds
and creases or moderate edema). No toxicities beyond
grade 2 were reported.
Table 3. Bivariate Analysis of Time to Local Recur-
rence
5-Year estimate (95% CI) Log-rank p-value
Patient’s age at diagnosis
(years)
£50 89.4 (94.9–78.9) 0.052
>50 97.0 (99.0–90.7)
Patient’s weight (lb)





African-American 90.9 (98.7–50.8) 0.768
Caucasian 94.1 (96.9–88.8)
Menopausal status




Yes 83.8 (92.1–68.4) 0.029
No 97.7 (99.2–92.9)
Method of initial detection
Mammography 94.5 (97.2–89.1) 0.531
Physical exam ⁄ other 92.2 (98.0–72.2)
Tumor size (cm)








Comedo 94.6 (98.0–86.1) 0.820
Non-comedo 93.4 (97.0–85.9)
Final surgical margins
Positive 62.5 (89.3–14.2) 0.002
Close 77.5 (92.3–44.8)
Negative 96.6 (98–91.8)
Total volume of excision
£60 cc3 93.4 (96.8–82.5) 0.329
>60 cc3 95.7 (98.6–87.2)
Adjuvant tamoxifen use
Yes 97.2 (99.6–81.9) 0.585
No 93.3 (96.5–87.5)
RT total dose (cGy)
£6000 95.3 (97.9–89.6) 0.126
>6000 89.4 (95.9–74.1)
RT delay
<90th %tile (72 days) 93.9 (96.8–88.6) 0.691
>90th %tile 94.7 (99.2–68.1)
Residual microcalcifications
on mammography
Yes 88.9 (97.1–62.4) 0.643
No 93.0 (96.8–84.8)
Table 4. Multivariate Cox Proportional Hazard
Model Predicting Local Recurrence (n = 198)
Hazard ratio 95% Confidence interval p-value
Patient’s age at
diagnosis (years)








Close 4.11 1.11–15.18 0.033
Positive 9.01 1.84–44.13 0.006
Figure 3. Overall and breast cancer-specific survival for all patients.
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The maximal acute toxicity grade was significantly
higher in women with larger separation (p < 0.001),
higher weight (p < 0.001), machine energy greater
than 6 MV (p < 0.001) and boost energy higher than
9 MeV (p < 0.001) or delivered by photons
(p < 0.001). In multivariate analyses, weight and
boost delivered by photons independently predicted
grade 2 toxicity (Table 5).
Cosmetic Outcome
Cosmetic evaluation was available for 159 patients
(85%). Fifteen women who had a mastectomy for
local recurrence were not included in the analyses.
This analysis refers to the last evaluation reported for
each patient. The median time between the end of RT
to the most recent cosmetic evaluation was 4.8 years
(range: 0.3–16.3 years). Cosmetic outcome was scored
as excellent in 119 patients (75%), good in 31 (19%),
fair in 8 (5%) and poor in 1 (1%).
Total volume of excision information was available
for 158 (79%) patients (Table 2). The median volume
was 65 cm3 for the 99 patients with excellent cosme-
sis, 131 cm3 for 25 patients with good cosmesis and
110 cm3 for seven patients with a fair cosmetic evalu-
ation. When comparing the median total volume of
excision between ‘‘excellent,’’ ‘‘good’’ and ‘‘fair’’ cat-
egories, smaller volume was a predictor for better cos-
metic outcome (p = 0.003). (The poor category was
dropped as a result of the small sample size, n = 1).
The total volume of excision did not uniformly
increase with the size of the tumor (p = 0.732).
When comparing the distribution of cases by
weight categories (101–130, 131–160, 161–200 and
201+ lbs) with the most recent cosmesis assessment,
there was a significant association between the two
covariates. Only 42% of patients in the heaviest
weight group achieved ‘‘excellent’’ score compared to
75%, 63%, and 72% in the 101–130, 131–160, and
161–200 lb categories, respectively (p = 0.012); forty-
two percent achieved only ‘‘good’’ score, as opposed
to 11%, 12%, and 15% in the lower three weight cat-
egories, respectively (p = .012).
Patients who received therapy with 6 MV only to
the whole breast were significantly more likely to
receive an excellent cosmetic assessment (67%) when
compared with patients treated with higher energy
photons (35%) (p = 0.002). Similarly, when the boost
was administered with electrons only (9–12 MeV)
compared to photons, a higher proportion of excellent
cosmetic results was achieved (62% and 71% for the
9 and 12 MeV, respectively versus 32% for any pho-
tons in the boost) (p = 0.03). Location of the primary
tumor in the breast (lateral versus medial versus cen-
tral) and age at diagnosis were not associated with
cosmetic outcome.
A multivariate logistic regression model was used
to determine independent predictors of an excellent
cosmetic assessment versus good or fair. When patient
weight, separation, total volume of excision, tumor
size, and beam energy were tested in the model, only
patient separation was found to significantly predict
cosmetic outcome (p = 0.004).
Complications
Complications included pneumonitis in two
patients (1%), and one patient each with chronic
breast ⁄ chest wall pain, decreased shoulder mobility,
cellulitis, and dermatosclerosis (<1%).
DISCUSSION
This study demonstrates high rates of local control
and excellent cosmetic results for patients with DCIS
treated with BCS and RT using lung density correc-
tion. The rates of local control compare favorably
with the results of randomized prospective trials of ad-
juvant RT for patients with DCIS after BCS (2–5) and
with other single institution retrospective studies (19–
22) of women with DCIS irradiated using unit-density
plans. Although differences in tumor characteristics
and statistical methods (e.g., tumor size, margin evalu-
ation, treatment factors, follow-up time and reporting
methods) can result in differences in rates of local con-
trol between studies, the findings presented here dem-
onstrate that treating patients with lung density
correction is at least as effective as unit density treat-
ment. Since treating the whole volume as unit density
results in an underestimation of breast dose by as
much as 10–20% (6,7), correction for the lung volume
will optimize the plan for better homogeneity and less
Table 5. Best Multivariate Model Predicting Grade
2 Maximal Acute Toxicity
Odds ratio 95% Confidence interval p-value
Weight (lb)
£200, n = 169 1.0
201+, n = 26 9.0 2.6–31.7 <0.001
Boost energy
Any photons, n = 20 5.1 1.4–19.1 0.015
All electrons, n = 180 1.0
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dose at the edges of the field. As previously shown, the
decreased attenuation of the photon beam by the lung
tissue compensates for the extra thickness of the breast
and eliminates the need for medial wedge (6). Thus,
the use of lung density correction optimizes the plan
and avoids regions of inhomogeneity in the medial,
lateral, and apical parts of the breast. The conse-
quences are reduced scatter dose to the opposite breast
by elimination of the medial wedge and reduction in
the monitor units required for the medial tangent (23).
The major factors associated with local recurrence
in our series were young age, family history of BC and
margin status. Young patients have been consistently
described as being at higher risk for local recurrence
compared with older patients following breast-conser-
ving treatment (2–4,7,21,22,24–28). Our results dem-
onstrate a failure rate of 3.1-fold for women age 50
and younger at diagnosis. The possible explanations
for this finding include the smaller excisional volume
described in younger patients (29), and a more aggres-
sive biologic phenotype in younger women with DCIS
as suggested by tumors associated with increased over-
expression of Her-2 ⁄ neu (30), and a higher proportion
of lesions with high nuclear grade and central necrosis
(29). Young women are also at higher risk of being
carriers of genetic mutations, such as BRCA1 ⁄ 2 or
other familial clusters for BC. In our series, family his-
tory of BC in a first- or second-degree relative was by
itself a significant risk factor for recurrence and could
be associated, in part, with genetic mutation carriers in
this population. Young women are less likely to die of
any other cause and therefore may have longer follow-
up periods to develop an in-breast recurrence.
Margin status is consistently reported as a risk fac-
tor for local recurrence after BCS and RT (2–4,20–
22,24,25,28,31) and our data are in agreement with
this finding. Variability exists regarding the width of
margins determined as negative in the above studies.
In the NSABP (3) and the EORTC trials (4) negative
margins are described as histologically tumor-free with
no quantitative measurement of the normal surround-
ing tissue. In the collaborative series reported by Solin
et al., all institutions declared negative margins as
2 mm or greater (28), and in the French Cancer Cen-
ter’s experience, negative margins were of 1 mm width
(21). The ‘‘Consensus Conference on the Treatment of
In Situ Ductal Carcinoma of the Breast’’ that was held
in 1999 by a panel of breast care experts reported that
achievement of negative margins was considered a
prerequisite for treatment of DCIS (32). Margin status
is of crucial importance because it is the only variable
the physician can control and that can be influenced
by treatment. While some investigators have recom-
mended 10 mm margins (33), such wide margins are
rarely achieved and can be associated with decreased
cosmetic results. The current study suggests that
3 mm minimum margins resulted in high rates of
tumor control while maintaining excellent cosmesis.
High nuclear grade has also been found to be asso-
ciated with local recurrence in large randomized trials
(31,34); therefore, nuclear grade determination is gen-
erally included in the pathology evaluation for
patients with DCIS, as was recommended in the
pathology consensus report in 1997 (35). However,
we found no evidence of a significant effect of nuclear
grade on the probability of local recurrence. Whether
this was due to the high percentage of women with
negative margins (‡3 mm) in the present series is
unclear. In other single institution reports in which
nuclear grade was reported in the majority of the
cohort, nuclear grade was also not significantly associ-
ated with local recurrence (20,22,26,36,37).
The rate of contralateral BC in the present series
was 4.3% at 5 years and 6.0% at 10 years, rates that
are in the lower range of the published data (3,4,19–
22,26,28,36,38). In a recent report by Solin et al. the
rates of CLBC were 4% and 9% at 5 and 10 years,
respectively, among 1003 women treated for DCIS
with BCS and RT in a multi-institutional report, with
a median follow-up of 8.5 years (28). Rodrigues et al.
reported a 7.1% rate of CLBC in a cohort of 515
patients treated with RT at a median follow-up of
7 years (19). The median follow-up of our series is
only 6.2 years and only 1% of our patients are
younger than age 35 at diagnosis. These factors could,
in part, explain the low rate of CLBC in our report,
as age has been reported as a risk factor for CLBC
(39). We cannot rule out that reduced scatter from
omission of the medial wedge made possible by the
use of lung density correction could have contributed
to the low rates of CLBC. Longer follow-up of our
patients, particularly the younger women, will be
required to assess the long-term effects of lung density
correction on rates of contralateral breast events.
Only 24% of the patients in our study were treated
with adjuvant tamoxifen. Tamoxifen was shown to
significantly reduce both local recurrence and contra-
lateral breast cancers in the NSABP B-24 trial (17),
where the 7-year rate of local recurrence was reduced
from 11.1% to 7.7% and the 7-year rate of CLBC
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was reduced from 4.9% to 2.3% when tamoxifen was
added to breast irradiation. Houghton et al. in the
UK ⁄ ANZ DCIS trial demonstrated a nonsignificant
reduction in ipsilateral local recurrence (15% versus
13%) and CLBC (3% versus 1%) with tamoxifen use
(5). Therefore, even lower rates of local recurrence
and contralateral breast cancers are possible by adding
tamoxifen as adjuvant treatment for women diagnosed
with DCIS and treated with BCS and RT. Since Janu-
ary 2003, all DCIS specimens are routinely evaluated
for the presence of estrogen receptor, and tamoxifen is
offered to patients with positive receptors.
Cosmetic outcome was scored as excellent or good
in 94% of the evaluated patients. Cosmetic outcome
after whole breast RT has been described as
good ⁄ excellent in 81–88% of patients with early stage
BC treated with BCS and RT, with the consistent find-
ing that patient separation is a predictor for cosmetic
outcome (40,41). Patient separation is measured at the
level of the isocenter, where the dose is usually pre-
scribed, and increasing separation is associated with
increasing dose inhomogeneity particularly at off-axis
points. Lung density correction improves the homo-
geneity inside the breast, which may help explain the
higher rates of good ⁄ excellent cosmesis in our study.
Obese women have greater separations and indeed
were found to have worse cosmesis. Also, for women
with larger breasts and separation, higher photon
energy for the whole breast and higher electron energy
or photons were used for the boost, explaining why
these factors were associated with less favorable
cosmesis and an increase in acute RT toxicity.
While our study demonstrates excellent rates of
tumor control and favorable cosmesis in women with
DCIS treated with lung density correction, we
acknowledge its limitations. It is a single institution
retrospective study with median total follow-up of
6.2 years. Additional follow-up is needed to insure
long-term local control and high rates of good ⁄ excel-
lent cosmesis. However, to the best of our knowledge,
this is the first study to report outcome in a series of
patients with DCIS treated with lung density correc-
tion and results compare favorably with other series
in which plans were calculated using unit density.
CONCLUSION
The findings indicate that BCS and RT treatment
for DCIS using lung density correction results in high
rates of local control and breast cancer-specific survi-
val at 5 and 10 years with excellent cosmetic results.
These results compare favorably with published
reports using non-corrected RT plans, and support the
routine use of lung density correction for breast-
conserving treatment for DCIS.
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